Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

MLA

Linden, Hannah M., et al. “Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 17, no. 14, July 2011, pp. 4799–805. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-10-3321.

APA

Linden, H. M., Kurland, B. F., Peterson, L. M., Schubert, E. K., Gralow, J. R., Specht, J. M., Ellis, G. K., Lawton, T. J., Livingston, R. B., Petra, P. H., Link, J. M., Krohn, K. A., & Mankoff, D. A. (2011). Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 17(14), 4799–4805. https://doi.org/10.1158/1078-0432.CCR-10-3321

Chicago

Linden, Hannah M, Brenda F Kurland, Lanell M Peterson, Erin K Schubert, Julie R Gralow, Jennifer M Specht, Georgiana K Ellis, et al. 2011. “Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 17 (14): 4799–4805. doi:10.1158/1078-0432.CCR-10-3321.